Acute Intermittent Porphyria Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Acute Intermittent Porphyria Market is segmented By Treatment (RNA Interference-based Therapy, Givosiran, Symptomatic Treatment), By Distribution Chan....
Acute Intermittent Porphyria Market Size
Market Size in USD
CAGR6.1%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.1% |
| Market Concentration | High |
| Major Players | Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe Pharma, Dicerna Pharmaceuticals, Moderna |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Acute Intermittent Porphyria Market Analysis
The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. The market has been expanding in recent years due to the rising prevalence of acute intermittent porphyria worldwide. Factors such as growing awareness about the condition and its treatment options are supporting the growth of this market.